Hexima Limited announced that it has been selected to present clinical data from its Phase I/IIa clinical trial of HXP 124 for the treatment of onychomycosis at the annual meeting of the American Podiatric Medical Association (APMA) in Aurora, Colorado in July 2021. The APMA represents an important venue for the presentation of HXP124's potential in onychomycosis. Podiatrists are the specialists who tend to manage most cases of onychomycosis and importantly write 80% of all prescriptions for onychomycosis in the US. Onychomycosis is a common fungal nail infection in the nail plate and nail bed. Prevalence of onychomycosis has been estimated at between 10% (Japan) and 13.8% (USA). Onychomycosis is an infectious disease with significant healthcare burden, it causes pain in approximately 50% of patients and in the US results in close to four doctor's visits annually for treatment. Onychomycosis impacts a patient's quality of life with 51% unable to wear the shoes they would prefer and 66% distressed by the appearance of their nail. It is important to treat onychomycosis as the fungi in the nail and can be a source of secondary infection in other areas of the body or infect family members and spread to the environment. Onychomycosis is the most common nail disorder, and the most common skin infection, accounting for 50% of all nail diseases. It is particularly prevalent in older, diabetic and immune compromised populations. The global market for treatments for onychomycosis was approximately USD 3.7 billion in 2018. Approved prescription therapies for onychomycosis comprise either oral or topical medications. Oral medications are associated with adverse effects such as nausea, taste disturbance, and flatulence. They can also severely impact liver function and so often require liver function monitoring. The clinical and commercial success of topical medications has been constrained by an inability of anti-fungal agents to effectively penetrate the human nail and the lack of sufficient anti-fungal activity when in contact with the target pathogen.